dfda compounded glp-1 receptor agonists Novo Nordisk Drops Hims & Hers: Inside the Crisis FDA Warns on Certain Forms

A Wells Pharmacy Network pharmacist will be happy to answer any questions

After consideration of these public comments, we are finalizing our proposal, without modification, to continue our current policy of utilizing a budget neutral 7.1 percent payment adjustment for rural SCHs, including EACHs, for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, brachytherapy sources, devices paid under the pass-through payment policy, and items paid at charges reduced to costs

The Centers for Medicare & Medicaid Services (CMS) recently said that broader access to GLP-1 drugs for weight loss could begin in Medicaid as early as May and in Medicare Part D in January 2027, under its BALANCE Model

A.SchenkerN.MengeB